BNTC icon

Benitec Biopharma

11.25 USD
+1.55
15.98%
At close Feb 14, 4:00 PM EST
After hours
11.35
+0.10
0.89%
1 day
15.98%
5 days
4.46%
1 month
8.38%
3 months
8.17%
6 months
29.46%
Year to date
-6.87%
1 year
301.79%
5 years
-86.10%
10 years
-91.70%
 

About: Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Employees: 16

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

186% more capital invested

Capital invested by funds: $44.3M [Q2] → $127M (+$82.4M) [Q3]

62.0% more ownership

Funds ownership: 67.88% [Q2] → 129.88% (+62.0%) [Q3]

32% more funds holding

Funds holding: 19 [Q2] → 25 (+6) [Q3]

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$17
51%
upside
Avg. target
$24
109%
upside
High target
$30
167%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Baird
Brian Skorney
22% 1-year accuracy
5 / 23 met price target
167%upside
$30
Outperform
Initiated
13 Dec 2024
Guggenheim
Debjit Chattopadhyay
32% 1-year accuracy
7 / 22 met price target
51%upside
$17
Buy
Reiterated
3 Dec 2024

Financial journalist opinion

Neutral
GlobeNewsWire
2 days ago
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024.
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Positive
Zacks Investment Research
1 month ago
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock
Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock
Positive
Zacks Investment Research
1 month ago
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
Positive
Zacks Investment Research
2 months ago
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
Neutral
GlobeNewsWire
2 months ago
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences.
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
Neutral
GlobeNewsWire
3 months ago
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29 th Annual Congress of the World Muscle Society-
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
Neutral
GlobeNewsWire
3 months ago
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024.
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
Positive
Seeking Alpha
4 months ago
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improvements in swallowing function and reduced pharyngeal residue, with no serious adverse events reported in the phase 1b/2a study. Financially, Benitec Biopharma is well-positioned with $50.9 million in cash, sufficient to fund operations through 2025, thanks to a $40 million PIPE financing.
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
Neutral
GlobeNewsWire
4 months ago
Benitec Biopharma Announces Updated Investor Webcast Information
-Management plans to host an investor webcast on October 14 th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below-
Benitec Biopharma Announces Updated Investor Webcast Information
Charts implemented using Lightweight Charts™